Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel

American Heart Journal

Volumn 165, Issue 2, 2013, Pages 176-182

  Gurbel, Paul A ^a   Bliden, Kevin P ^a   Fort, John G ^b   Jeong, Young Hoon ^a   Shuldiner, Alan ^c   Chai, Sumbul ^c   Gesheff, Tania ^a   Antonino, Mark ^a   Gesheff, Martin ^a   Zhang, Ying ^b   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b POZEN Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PA 32540; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; ECCHYMOSIS; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ASPIRIN; CORONARY THROMBOSIS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TABLETS, ENTERIC-COATED; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84872867830     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.07.032     Document Type: Article

References (13)

1. G.N. Levine, E.R. Bates, and J.C. Blankenship American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
2. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 56 2010 2051 2066
3. P.A. Gurbel, U.S. Tantry, and D. Kereiakes Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases Drug Healthc Patient Safe 2 2010 233 240
4. P.A. Gurbel, K.P. Bliden, and J. Fort Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study Clin Pharmacol Ther 90 2011 860 866
5. J.L. Ferreiro, M. Ueno, and D. Capodanno Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study Circ Cardiovasc Interv 3 2010 436 441
6. D.J. Angiolillo, C.M. Gibson, and S. Cheng Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2011 65 74
7. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
8. G.V. Moukarbel, and D.L. Bhatt Antiplatelet therapy and proton pump inhibition: clinician update Circulation 125 2012 375 380
9. S.G. Goodman, R. Clare, K.S. Pieper on behalf of the Platelet Inhibition and Patient Outcomes (PLATO) Trial Investigators Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO Circulation 125 2012 978 986
10. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
11. J.M. Wo, J. Eversmann, and S. Mann Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis Aliment Pharmacol Ther 31 2010 516 520
12. B.W. Ogilvie, P. Yerino, and F. Kazmi The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel Drug Metab Dispos 39 2011 2020 2033
13. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175